Stratus™ Medical receives CE Mark for Nimbus® RF Multitined Expandable Electrode and Vesta™ RF Cannula prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Proprietary Resin Technology for Dental Prosthetics Delivering Superior Strength, Aesthetics and Function for Patients to Be Available to European Dental Professionals Beginning This Summer Developed
Proprietary Resin Technology for Dental Prosthetics Delivering Superior Strength, Aesthetics and Function for Patients to Be Available to European Dental Professionals Beginning This SummerDeveloped, tested, and selected from more than 200 formulationsUnique long-chain chemistry formulated and optimized for 3D print.
Posted on 175
Fibralign Corp., a Stanford spin-out and developer of therapeutic biomedical devices, today announced enrollment of the first patient in a multi-site, randomized clinical trial in Europe evaluating its BioBridge® Collagen Matrix as a novel preventative treatment for secondary lymphedema.
The study plans to enroll 40 patients that have been diagnosed with advanced stage breast cancer and require axillary lymph node dissection (ALND), a common surgical intervention that involves removal of compromised lymph nodes to address the spread of cancer. Peer reviewed publications have estimated that 15-25% of patients who undergo ALND develop breast cancer-related lymphedema (BCRL) due to the surgery. ALND combined with radiation therapy increases the likelihood of BCRL further up to 40%.
Fibralign Corporation: Fibralign Announces Start of European Lymphedema Prevention Clinical Study
Multi-site clinical study to evaluate BioBridge as prophylactic treatment for at-risk patients
Fibralign Corp., a Stanford spin-out and developer of therapeutic biomedical devices, today announced enrollment of the first patient in a multi-site, randomized clinical trial in Europe evaluating its BioBridge Collagen Matrix as a novel preventative treatment for secondary lymphedema.
The study plans to enroll 40 patients that have been diagnosed with advanced stage breast cancer and require axillary lymph node dissection (ALND), a common surgical intervention that involves removal of compromised lymph nodes to address the spread of cancer. Peer reviewed publications have estimated that 15-25% of patients who undergo ALND develop breast cancer-related lymphedema (BCRL) due to the surgery. ALND combined with radiation therapy increases the likelihood of BCRL further up to 40%.